Form 8-K PMV Pharmaceuticals, For: Nov 07
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/28/2026
- Wall St declines as oil spikes after Trump rejects Iran peace proposal
- S&P 500 breadth hits lowest level since dot-com bubble, Goldman says
- Nvidia’s AI dominance funds historic $150 billion buyback
- MongoDB stock drops 15% as CEO Desai resigns for Meta
- Jefferies cuts Roblox to Underperform, says rally is too optimistic
- Bloom Energy shares fall on Oracle project halt
- Oppenheimer sees AI software winners as focus shifts to ROI
- Exclusive-Activist Jana pushes Fiserv to accelerate cost cuts and tap Palantir
- Cantor Fitzgerald Starts Lexicon Pharmaceuticals (LXRX) at Overweight
- Arm Holdings falls as CFO stock sale weighs on sentiment
Oppenheimer Upgrades PMV Pharmaceuticals Inc. (PMVP) to Outperform
November 8, 2024 6:04 AM ESTOppenheimer analyst Jeff Jones upgraded PMV Pharmaceuticals Inc. (NASDAQ: PMVP) from Perform to Outperform with a price target of $6.00.
The analyst comments "On Thursday, PMV Pharmaceuticals reported 3Q results and provided a business update. The Phase 2/pivotal monotherapy trial for rezatapopt remains on... More
